IP Library › Granted Patent US 12,215,137
Granted Patent B2
US 12,215,137 · App. 17/038,676 · Granted Feb 4, 2025

Compositions and methods for T cell delivery of therapeutic molecules

Inventors: Yangbing Zhao (Lumberton, NJ); Carl H. June (Merion Station, PA); Xiaojun Liu (Wallingford, PA)
Assignee: The Trustees of the University of Pennsylvania
C07K14/70578A61K39/39558A61K39/4611A61K39/4631A61K39/464406A61K39/464412C07K14/70521C07K14/71C07K14/7155C07K16/2818C07K16/2827C07K16/2863C12N5/0636C12N15/00C07K2317/31C07K2317/622C07K2319/02C07K2319/10C07K2319/74C12N2501/515C12N2501/599C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,215,137
App. No.
17/038,676
Granted
Feb 4, 2025
Kind
B2
Abstract

The present invention includes compositions and methods for modifying a T cell with a nucleic acid encoding a switch molecule comprising an extracellular domain comprising a membrane receptor or fragment thereof and an intracellular domain comprising a signaling receptor or fragment thereof. In one aspect, a method comprises introducing a nucleic acid encoding a switch molecule and a nucleic acid encoding a soluble fusion protein and/or a nucleic acid encoding a bispecific antibody into a population of cells comprising T cells, wherein the T cells transiently expresses the switch molecule and soluble fusion protein or bispecific antibody. In other aspect, compositions of T cells and methods of treating a disease or condition, such as cancer or an autoimmune disease, are also included.

Claims (36)

1. A method for enhancing T cell antitumor activity in a subject in need thereof, the method comprising parenterally administering to the subject a composition comprising modified CAR T cells comprising a nucleic acid sequence encoding a switch molecule and a nucleic acid sequence encoding a CAR comprising an antigen binding domain that targets a tumor antigen, a transmembrane domain, a costimulatory domain, and an intracellular signaling domain;

wherein the switch molecule comprises:

(a) an extracellular domain of a transforming growth factor-beta receptor (TGF-beta-R), an intracellular domain of a signaling receptor selected from the group consisting of interleukin-12 receptor (IL-12R), CD3, CD28, CD137, CD27, ICOS, and OX40, and a transmembrane domain derived from the same molecule as the extracellular domain or the same molecule as the intracellular domain;

(b) an extracellular domain of a programmed cell death 1 (PD1) receptor, an intracellular domain of a signaling receptor selected from the group consisting of interleukin-12 receptor (IL-12R), CD3, CD28, CD137, CD27, ICOS, and OX40, and a transmembrane domain derived from the same molecule as the extracellular domain or the same molecule as the intracellular domain;

(c) an extracellular domain of a programmed cell death ligand 1 (PDL1) receptor, an intracellular domain of a signaling receptor selected from the group consisting of interleukin-12 receptor (IL-12R), CD3, CD28, CD137, CD27, ICOS, and OX40, and a transmembrane domain derived from the same molecule as the extracellular domain or the same molecule as the intracellular domain; or

(d) an extracellular domain of an interferon-gamma receptor (IFN-gamma) receptor, an intracellular domain of a signaling receptor selected from the group consisting of interleukin-12 receptor (IL-12R), CD3, CD28, CD137, CD27, ICOS, and OX40, and a transmembrane domain derived from the same molecule as the extracellular domain or the same molecule as the intracellular domain;

wherein the modified CAR T cells home to a target tumor site; and

wherein when the modified CAR T cells express the switch molecule, interaction of the extracellular domain of the switch molecule with TGFβ, PD1, PDL1, or IFN-γ in the tumor microenvironment converts an inhibitory signal of the TGFβ receptor, the PD1 receptor, the PDL1 receptor, or the IFN-γ receptor into an IL-12R, CD3, CD28, CD137, CD27, ICOS, or OX40 stimulatory signal thereby enhancing the antitumor activities of the modified CAR T cells.

2. The method according to claim 1 , wherein the switch molecule comprises the extracellular domain of TGF-beta-R.

3. The method according to claim 2 , wherein the signaling receptor is IL-12R.

4. The method according to claim 1 , wherein the nucleic acid comprises in vitro transcribed RNA or synthetic RNA.

5. The method according to claim 1 , wherein enhancing the antitumor activities of the modified CAR T cells comprises inducing a secretion of an activation factor at the target tumor site, and wherein the activation factor is a soluble cytokine selected from the group consisting of IL-1, IL-2, IL-6, IL-7, IL-8, IL-10, IL-12, IL-15, IL-21, TNF, TGF, IFN, and functional fragments and variants thereof.

6. The method according to claim 1 , wherein the tumor target site is selected from the group consisting of brain cancer, bladder cancer, breast cancer, cervical cancer, colorectal cancer, liver cancer, kidney cancer, lymphoma, leukemia, lung cancer, melanoma, metastatic melanoma, mesothelioma, neuroblastoma, ovarian cancer, prostate cancer, pancreatic cancer, renal cancer, skin cancer, thymoma, sarcoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, uterine cancer, and combinations thereof.

7. The method according to claim 1 , wherein the modified CAR T cells home to a solid tumor site.

8. The method according to claim 1 , wherein the modified CAR T cells home to a cancer expressing a tumor antigen selected from the group consisting of p53, Ras, beta-Catenin, CDK4, alpha-Actinin-4, Tyrosinase, TRP1/gp75, TRP2, gp100, Melan-A/MART1, Gangliosides, PSMA, HER2, WT1, EphA3, EGFR, CD19, CD20, MAGE, BAGE, GAGE, NY-ESO-1, Telomerase, Survivin, and any combination thereof.

9. The method according to claim 8 , wherein the modified CAR T cells express a nucleic acid encoding TGF-beta-IL-12 switch molecule and a nucleic acid encoding a CD19 CAR or a HER2 CAR.

10. The method according to claim 1 , wherein the modified CAR T cells are activated.

11. The method according to claim 1 , wherein the modified CAR T cells induce lysis of cells and/or tissues at the tumor target site.

12. The method according to claim 1 , wherein the modified CAR T cells are cryopreserved.

13. The method according to claim 1 , wherein the subject is a human.

14. The method according to claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier.

15. The method according to claim 1 , wherein the CAR targets a tumor antigen selected from the group consisting of TRP1/gp75, TRP2, gp100, Melan-A/MART1, Gangliosides, PSMA, HER2, WT1, EphA3, EGFR, CD19, CD20, MAGE, and NY-ESO-1.

16. The method according to claim 1 , wherein the switch molecule is expressed transiently.

17. The method according to claim 1 , wherein the composition is administered to the subject more than once.

18. The method according to claim 1 , wherein the modified CART cells are autologous or allogeneic to the subject.

19. The method according to claim 1 , wherein the antitumor activity is for a cancer selected from the group consisting of brain cancer, bladder cancer, breast cancer, cervical cancer, colorectal cancer, liver cancer, kidney cancer, lymphoma, leukemia, lung cancer, melanoma, metastatic melanoma, mesothelioma, neuroblastoma, ovarian cancer, prostate cancer, pancreatic cancer, renal cancer, skin cancer, thymoma, sarcoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, uterine cancer, and combinations thereof.

20. The method according to claim 1 , wherein the transmembrane domain is a CD28 transmembrane domain.

21. A method for enhancing T cell antitumor activity in a subject in need thereof, the method comprising parenterally administering to the subject a composition comprising modified T cells comprising a nucleic acid sequence encoding a switch molecule and a nucleic acid sequence encoding a chimeric antigen receptor (CAR) that targets a tumor antigen,

wherein the tumor antigen is selected from the group consisting of p53, Ras, beta-Catenin, CDK4, alpha-Actinin-4, Tyrosinase, TRP1/gp75, TRP2, gp100, Melan-A/MART1, Gangliosides, PSMA, HER2, WT1, EphA3, EGFR, CD19, CD20, MAGE, BAGE, GAGE, NY-ESO-1, telomerase, and survivin;

wherein the switch molecule comprises:

(a) an extracellular domain of a transforming growth factor-beta receptor (TGF-beta-R), an intracellular domain of a signaling receptor selected from the group consisting of interleukin-12 receptor (IL-12R), CD3, CD28, CD137, CD27, ICOS, and OX40, and a transmembrane domain derived from the same molecule as the extracellular domain; or the same molecule as the intracellular domain;

(b) an extracellular domain of a programmed cell death 1 (PD1) receptor, an intracellular domain of a signaling receptor selected from the group consisting of interleukin-12 receptor (IL-12R), CD3, CD28, CD137, CD27, ICOS, and OX40, and a transmembrane domain derived from the same molecule as the extracellular domain, or the same molecule as the intracellular domain;

(c) an extracellular domain of a programmed cell death ligand 1 (PDL1) receptor, an intracellular domain of a signaling receptor selected from the group consisting of interleukin-12 receptor (IL-12R), CD3, CD28, CD137, CD27, ICOS, and OX40, and a transmembrane domain derived from the same molecule as the extracellular domain, or the same molecule as the intracellular domain; or

(d) an extracellular domain of an interferon-gamma receptor (IFN-gamma) receptor, an intracellular domain of a signaling receptor selected from the group consisting of interleukin-12 receptor (IL-12R), CD3, CD28, CD137, CD27, ICOS, and OX40, and a transmembrane domain derived from the same molecule as the extracellular domain, or the same molecule as the intracellular domain;

wherein the modified T cells home to a target tumor site; and

wherein when the modified T cells express the switch molecule, interaction of the extracellular domain of the switch molecule with TGFβ, PD1, PDL1, or IFN-γ in the tumor site converts the inhibitory signal of the TGFβ receptor, the PD1 receptor, the PDL1 receptor, or the IFN-γ receptor into the IL-12R, the CD3, the CD28, the CD137, the CD27, the ICOS, or the OX40 stimulatory signal, thereby enhancing antitumor activities of the modified T cells.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2024
From: ZHAO, YANGBING; LIU, XIAOJUN; JUNE, CARL H.
To: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 069597/0142 →
Continuity (3)
Division 15544816
Provisional Application 62110489 · Jan 31, 2015
Related Publication 20210008188A1 · Jan 14, 2021
References Cited (123)
US 4444887A · Hoffmann · 1984 [cited by applicant]
US 4676980A · Segal et al. · 1987 [cited by applicant]
US 4716111A · Osband et al. · 1987 [cited by applicant]
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 5199942A · Gillis et al. · 1993 [cited by applicant]
US 5225539A · Winter · 1993 [cited by applicant]
US 5229275A · Goroff et al. · 1993 [cited by applicant]
US 5350674A · Boenisch et al. · 1994 [cited by applicant]
US 5413923A · Kucherlapati et al. · 1995 [cited by applicant]
US 5530101A · Queen et al. · 1996 [cited by applicant]
US 5545806A · Lonberg et al. · 1996 [cited by applicant]
US 5565332A · Hoogenboom et al. · 1996 [cited by applicant]
US 5567610A · Borrebaeck et al. · 1996 [cited by applicant]
US 5569825A · Lonberg et al. · 1996 [cited by applicant]
US 5573905A · Lerner et al. · 1996 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 5585362A · Wilson et al. · 1996 [cited by applicant]
US 5625126A · Lonberg et al. · 1997 [cited by applicant]
US 5633425A · Lonberg et al. · 1997 [cited by applicant]
US 5661016A · Lonberg et al. · 1997 [cited by applicant]
US 5731168A · Carter et al. · 1998 [cited by applicant]
US 5814318A · Lonberg et al. · 1998 [cited by applicant]
US 5939598A · Kucherlapati et al. · 1999 [cited by applicant]
US 6120766A · Hale et al. · 2000 [cited by applicant]
US 6331415B1 · Cabilly et al. · 2001 [cited by applicant]
US 6548640B1 · Winter · 2003 [cited by applicant]
US 7585960B2 · Hanke et al. · 2009 [cited by applicant]
US 8147834B2 · Wu · 2012 [cited by applicant]
US 9073968B2 · Nishimura et al. · 2015 [cited by applicant]
US 9315559B2 · Spencer et al. · 2016 [cited by applicant]
US 9688740B2 · Choi · 2017 [cited by applicant]
US 10584158B2 · Valdes · 2020 [cited by applicant]
US 20060025576A1 · Miller et al. · 2006 [cited by applicant]
US 20090055944A1 · Korman et al. · 2009 [cited by applicant]
US 20110280878A1 · Honjo et al. · 2011 [cited by applicant]
US 20140050709A1 · Leen et al. · 2014 [cited by applicant]
US 20140219975A1 · June et al. · 2014 [cited by applicant]
US 20200140520A1 · Vera Valdes · 2020 [cited by applicant]
AU 2006265108A1 · 2007 [cited by applicant]
EP 519596A1 · 1992 [cited by applicant]
EP 592106A1 · 1994 [cited by applicant]
EP 239400B1 · 1994 [cited by applicant]
EP 3207147 · 2017 [cited by applicant]
WO 9109967A1 · 1991 [cited by applicant]
WO 9308829A1 · 1993 [cited by applicant]
WO 9633735A1 · 1996 [cited by applicant]
WO 9634096A1 · 1996 [cited by applicant]
WO 9824893A2 · 1998 [cited by applicant]
WO 2009089004A1 · 2009 [cited by applicant]
WO 2013019615A2 · 2013 [cited by applicant]
WO 2014011988A2 · 2014 [cited by applicant]
WO 2014165707A2 · 2014 [cited by applicant]
WO 2014172584A1 · 2014 [cited by applicant]
WO 2015009604A1 · 2015 [cited by applicant]
WO 2016061574A1 · 2016 [cited by applicant]
WO 2016122738 · 2016 [cited by applicant]
Kakarla, et al. (2014) “CAR T cells for solid tumors: armed and ready to go?”, Cancer Journal, 20(2): 151-55, provided here by way of NIH public access author manuscript, 11 pages long. (Year: 2014). [cited by examiner]
Morgan, et al. (2010) “Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2”, Molecular Therapy, 18(4): 843-51. (Year: 2010). [cited by examiner]
Yang, et al. (2022) “CAR-T Cell Therapy for Breast Cancer: From Basic Research to Clinical Application”, International Journal of Biological Sciences 2609-26. (Year: 2022). [cited by examiner]
Scalea, et al. (2012) “T-cell-mediated immunological barriers to xenotransplantation” Xenotransplantation, 19: 23-30. (Year: 2012). [cited by examiner]
Wang, et al. (Mar. 14, 2017) “Mechanism of immune evasion in breast cancer”, OncoTargets and Therapy, 10: 1561-73. (Year: 2017). [cited by examiner]
European Office Action issued in EP15880617.4, dated Nov. 13, 2020, 5 pages. [cited by applicant]
Supplementary European Search Report dated Jun. 20, 2018 for European Patent Application No. 15880617.4. [cited by applicant]
Examination report dated Mar. 31, 2021 for Australian Patent Application No. 2015380397. [cited by applicant]
Sims , et al., “A humanized CD18 antibody can block function without cell destruction”, J. Immunol., 151:2296-2308 (1993). [cited by applicant]
Stepinski , et al., “Synthesis and propertys of mRNAs containing the novel “anti-reverse” cap analogs 7-methyl(3′-O-methyl) GpppG and 7-methyl(3′-deoxy)GpppG”, 2001, RNA, 7:1468-95. [cited by applicant]
Studnicka , et al., “Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues”, Protein Engineering, 7(6):805-814 (1994). [cited by applicant]
Traunecker , et al., “Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells”, EMBO J. 10: 3655-9 (1991). [cited by applicant]
Tutt , et al., “Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells”, J. Immunol. 147: 60-9 (1991) (abstract). [cited by applicant]
Vaughan , et al., “Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library.”, Vaughan et al., 1996, Nature Biotech., 14:309-14 (Abstract). [cited by applicant]
Verhoeyen , et al., “Reshaping human antibodies: grafting an antilysozyme activity”, Science, 239:1534-1536 (1988). [cited by applicant]
Watanabe , et al., “A distinct role for ICOS-mediated co-stimulatory signaling in CD4+ and CD8+ T cell subsets.”, 2005, International Immunology 17(3):269-278. [cited by applicant]
Wu , et al., “Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.”, J. Mol. Biol., 294:151-162 (1999). [cited by applicant]
European Patent Application No. 15880617.4—Communication pursuant to Article 94(3) EPC issued Jul. 3, 2019. [cited by applicant]
European Search Report dated Jun. 27, 2018 for European Patent Application No. 15880617. [cited by applicant]
International Search Report and Written Opinion dated Feb. 26, 2016 for PCT/US15/58192. [cited by applicant]
Japanese Patent Application No. 2017-540269—First Notice of Reasons for Rejection issued Nov. 8, 2019. [cited by applicant]
Aoki , “Transforming growth factor beta (TGF-beta) and autoimmunity.”, 2005, Autoimmunity Reviews 4:450-459. [cited by applicant]
Bierer , et al., “Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology.”, Current Opinion in Immunology 1993, 5:763-773. [cited by applicant]
Bird , et al., “Single-Chain Antigen-Binding Proteins”, 1988, Science 242(4877):423-426. [cited by applicant]
Brennan , et al., “Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments.”, Science. Jul. 5, 1985;229(4708):81-3 (Abstract). [cited by applicant]
Bruggerman , et al., “Designer Mice: The Production of Human Antibody Repertoires in Transgenic Animals.”, 1993, Year in Immunol 7:33-40. [cited by applicant]
Carter , et al., “Humanization of an anti-p185HER2 antibody for human cancer therapy.”, 1992, Proc Natl Acad Sci USA 89:4285-4289. [cited by applicant]
Chothia , et al., “Canonical structures for the hypervariable regions of immunoglobulins.”, J Mol Biol. Aug. 20, 1987;196(4):901-17. (Abstract). [cited by applicant]
Clackson , et al., “Making antibody fragments using phage display libraries”, Nature, 352:624-628 (1991) (abstract). [cited by applicant]
Claus , et al., “CD27 Signaling Increases the Frequency of Regulatory T Cells and Promotes Tumor Growth.”, 2012, Cancer Research 72(14):3664-76. [cited by applicant]
Cougot , et al., “‘Cap-tabolism’.”, Trends Biochem Sci. Aug. 2004;29(8):436-44. (Abstract). [cited by applicant]
Donnelly , et al., “Gene Therapy for Cystic Fibrosis Lung Disease: Overcoming the Barriers to Translation to the Clinic.”, 2018, Frontiers in Pharmacology 9: article 1381 (8 pages). [cited by applicant]
Duchosal , et al., “Immunization of hu-PBL-SCID mice and the rescue of human monoclonal Fab fragments through combinatorial libraries.”, 1992, Nature 355:258-262. [cited by applicant]
Dudley , et al., “Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients”, J Immunother. Jul.-Aug. 2003;26(4), Jul.-Aug. 2003, 332-342. [cited by applicant]
Elango , et al., “Optimized transfection of mRNA transcribed from a d(A/T)100 tail-containing vector”, Biochim. Biophys. Res. Commun. 330, 2005, 958-966 (abstract only). [cited by applicant]
Griffiths , et al., “Human anti-self antibodies with high specificity from phage display libraries.”, The EMBO Journal vol. 12, No. 2, pp. 725-734, 1993. [cited by applicant]
Gruber , et al., “Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in [cited by applicant]
Henderson , et al., “Comparison of the effects of FK-506, cyclosporine A and rapamycin on IL-2 production.”, Immun. 73:316-321, 1991. [cited by applicant]
Hollinger , et al., “‘Diabodies’: Small bivalent and bispecific antibody fragments.”, Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993). [cited by applicant]
Hoogenboom , et al., “By-passing immunization. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro”, J. Mol. Biol. 227, 1991, 381-388 (Abstract Only). [cited by applicant]
Huse , “The T-cell-receptor signaling network.”, 2009, Cell Science at a Glance, Journal of Cell Science 122 (9):1269-73 (Year 2009). [cited by applicant]
Huston , “Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in [cited by applicant]
Jakobovits , et al., “Analysis of homozygous mutant chimeric mice: Deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production”, Proc. Natl. Acad. Sci. 90, 1993, 2551-2555. [cited by applicant]
Jakobovits , et al., “Germ-line transmission and expression of a human-derived yeast artificial chromosome.”, 1993, Nature 362:255-258. [cited by applicant]
Johnson , et al., “Human antibody engineering”, Current Opinion in Structural Biology 3:564-571 (1993). [cited by applicant]
Jones , et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse”, Nature, 321:522-525 (1986). [cited by applicant]
Kostelny , et al., “Formation of a bispecific antibody by the use of leucine zippers”, “Formation of a bispecific antibody by the use of leucine zippers,” J. Immunol., vol. 148, No. 5, pp. 1547-1553 (1992), 1992, 1547-1… [cited by applicant]
Kusaba , et al., “Interleukin-12-induced Interforon-gamma Production by Human Peripheral Blood T Cells Is Regulated by Mammalian Target of Rapamycin (mTOR).”, 2005, J Biol Chem 280(2):1037-1043. [cited by applicant]
Lee , “4-1BB Signaling Activates the T Cell Factor 1 Effector/beta-Catenin Pathway with Delayed Kinetics via ERK Signaling and Delayed PI3K/AKT Activation to Promote the Proliferation of CD8+ T Cells.”, 2013, PLOS One 8… [cited by applicant]
Liu , et al., “Calcineurin Is a Common Target of Cyclophilin-Cyclosporin A and FKBP-FK506 Complexes”, Cell 66:807-815, 1991. [cited by applicant]
Lonberg , et al., “Human antibodies from transgenic mice.”, Int. Rev. Immunol., 13:65-93 (1995). [cited by applicant]
Marks , et al., “By-passing immunization. Human antibodies from V-gene libraries displayed on phage”, J. Mol. Biol. 222:581-597 (1991). [cited by applicant]
McCafferty , et al., “Phage antibodies: filamentous phage displaying antibody variable domains”, Nature 348, 1990, 552-554. [cited by applicant]
Milstein , et al., “Hybrid hybridomas and their use in immunohistochemistry”, (1983) Nature 305: 537-39. (abstract). [cited by applicant]
Nacheva , et al., “Preventing nondesired RNA-primed RNA extension catalyzed by T7 RNA polymerase”, 2003, Eur. J. Biochem., 270:1458-65. [cited by applicant]
Nishikawa , et al., “Nonviral vectors in the new millennium: delivery barriers in gene transfer.”, Hum Gene Ther., 12(8):861-70 (2001) (Abstract). [cited by applicant]
Oh , et al., “TGF-beta: Guardian of T Cell Function”, 2013, J. Immunol. 191:3973-3979. [cited by applicant]
Padlan , “A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties”, 1991, Molecular Immunology, 28(4/5):489-498. [cited by applicant]
Presta , et al., “Humanization of an antibody directed against IgE”, J. Immunol., 151:2623-32 (1993). [cited by applicant]
Redmond , et al., “The role of OX40-mediated co-stimulation in T cell activation and survival.”, 2009, Crit Rev Immunol 29(3):187-201. [cited by applicant]
Riechmann , et al., “Reshaping human antibodies for therapy”, Nature, 332:323-327 (1988). [cited by applicant]
Riechmann , “Single domain antibodies: comparison of camel VH and camelised human VH domains”, 1999, Journal of Immunological Methods 231:25-38. [cited by applicant]
Riha , et al., “CD28 co-signaling in the adaptive immune response.”, Landes Bioscience 1(3):231-40 (Year: 2010). [cited by applicant]
Roder , et al., “The EBV-hybridoma technique”, Methods Enzymol., 121:140-167 (1986). [cited by applicant]
Roguska , et al., “Humanization of murine monoclonal antibodies through variable domain resurfacing”, PNAS, 91:969-973 (1994). [cited by applicant]
Rosenberg , et al., “Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.”, New Eng. J. of Med. 319:1676-80, 1988). [cited by applicant]
Schenborn , et al., “A novel transcription property of SP6 and T7 RNA polymerases: dependence on template structure”, 1985, Nuc Acids Res., 13:6223-36. [cited by applicant]